Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH phase II study of AZD2014 with optional rituximab in relapsed or refractory DLBCL
2014-003588-39Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vistusertib and rituximab in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by University of Birmingham. Primary endpoint: Best overall response rate during first 6 cycles. Started Apr 2015; status: completed.
02
Drugs
vistusertibrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2014-003588-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003588-39.